

Wegovy - (0.25 mg/0.5 mL, 0.5 mg/0.5 mL, 1 mg/0.5 mL, 1.7 mg/0.75 mL, 2.4 mg/0.75 mL ; Solution, Subcutaneous)

Generic Name	Semaglutide	Innovator	Novo Nordisk
Dosage	0.25 mg/0.5 mL, 0.5 mg/0.5 mL, 1 mg/0.5 mL, 1.7 mg/0.75 mL, 2.4 mg/0.75 mL ; Solution, Subcutaneous	Branded US Sales	More Than \$1000 mn
Probable FTF	Less Than 5	Known Para IV Filers	Less Than 5
Other ANDA developers	More Than 5	Tentative Approvals	None
Final Approvals	None	Generic Launches	None
Indication	WEGOVY is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in adult patients		
Complexities	Yes		

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Wegovy - (1.5MG, 4MG, 9MG, 25MG ; Tablet)

Generic Name	Semaglutide	Innovator	Novo Nordisk
Dosage	1.5MG, 4MG, 9MG, 25MG ; Tablet	Branded US Sales	More Than \$1000 mn
Probable FTF	Less Than 5	Known Para IV Filers	Less Than 5
Other ANDA developers	More Than 5	Tentative Approvals	None
Final Approvals	None	Generic Launches	None
Indication	WEGOVY is a glucagon-like peptide-1 (GLP-1) receptor agonist. WEGOVY tablets are indicated in combination with a reduced calorie diet and increased physical activity: • To reduce the risk of major adverse CV events (CV death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established CV disease and either obesity or overweight. • To reduce excess body weight and maintain weight reduction long term in adults with obesity, or in adults with overweight in the presence of at least one weight-related comorbid condition.		
Complexities	Yes		

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Wegovy - (0.25MG/0.5ML (0.25MG/0.5ML), 0.5MG/0.5ML (0.5MG/0.5ML), 1MG/0.5ML (1MG/0.5ML), 1.7MG/0.75ML (1.7MG/0.75ML), 2.4MG/0.75ML (2.4MG/0.75ML); SOLUTION)

Generic Name	Semaglutide	Innovator	None
Dosage	0.25MG/0.5ML (0.25MG/0.5ML), 0.5MG/0.5ML (0.5MG/0.5ML), 1MG/0.5ML (1MG/0.5ML), 1.7MG/0.75ML (1.7MG/0.75ML), 2.4MG/0.75ML (2.4MG/0.75ML); SOLUTION	Branded US Sales	Less Than \$1000 mn
Probable FTF	None	Known Para IV Filers	None
Other ANDA developers	None	Tentative Approvals	None
Final Approvals	None	Generic Launches	None
Indication	WEGOVY is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in: • adult patients with an initial body mass index (BMI) of o 30 kg/m2 or greater (obesity) or o 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia). • pediatric patients aged 12 years and older with an initial BMI at the 95th percentile or greater for age and sex (obesity).		
Complexities	Yes		

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.